Five Days of No Anticoagulation or Antiplatelet Therapy and NovoSeven Administration in a HeartWare HVAD Patient

Artificial Organs

Volumn 36, Issue 8, 2012, Pages 751-753

  Saeed, Diyar ^a   Albert, Alexander ^a   Kamiya, Hiroyuki ^a   Maxhera, Bujar ^a   Westenfeld, Ralf ^a   Lichtenberg, Artur ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Anticoagulation; Bleeding; Cardiac surgery; NovoSeven; Recombinant factor VIIa; Ventricular assist device

Indexed keywords

ARTIFICIAL HEART; CARDIOVASCULAR SURGERY; FIBER OPTIC SENSORS;

ANTI-COAGULATION; ANTICOAGULATION THERAPY; ANTIPLATELETS THERAPY; BLEEDINGS; CARDIAC-SURGERY; CASE REPORTS; NOVOSEVEN; RECOMBINANT FACTOR VIIA; VENTRICULAR ASSIST DEVICE; VENTRICULAR ASSIST DEVICE-;

LEFT VENTRICULAR ASSIST DEVICES;

ACETYLSALICYLIC ACID; ARGATROBAN; HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; EXTRACORPOREAL OXYGENATION; HEART ASSIST DEVICE; HEART RIGHT ATRIUM; HEART SURGERY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SUPERIOR CAVA VEIN; THORACOTOMY; THROMBUS; TUBE;

EID: 84864821828     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2012.01473.x     Document Type: Article

References (10)

1. Jennings D, McDonnell J, Schillig J. Assessment of long-term anticoagulation in patients with a continuous-flow left-ventricular assist device: a pilot study. J Thorac Cardiovasc Surg 2011;142:e1-2.
2. Slaughter MS. Hematologic effects of continuous flow left ventricular assist devices. J Cardiovasc Transl Res 2010;3:618-24.
3. Crow S, Chen D, Milano C, etal. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg 2010;90:1263-9; discussion 1269.
4. Valentino LA, Cooper DL, Goldstein B. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia 2011;17:579-89.
5. Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology Am Soc Hematol Educ Program 2010;2010:153-9.
6. Monroe DM, Roberts HR. Mechanism of action of high-dose factor VIIa: points of agreement and disagreement. Arterioscler Thromb Vasc Biol 2003;23:8-9; discussion 10.
7. Uhlmann EJ, Eby CS. Recombinant activated factor VII for non-hemophiliac bleeding patients. Curr Opin Hematol 2004;11:198-204.
8. Gandhi MJ, Pierce RA, Zhang L, Moon MR, Despotis GJ, Moazami N. Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant. J Cardiothorac Surg 2007;2:32.
9. Bruckner BA, DiBardino DJ, Ning Q, etal. High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII. J Heart Lung Transplant 2009;28:785-90.
10. Apostolidou I, Sweeney MF, Missov E, Joyce LD, John R, Prielipp RC. Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia. Anesth Analg 2008;106:404-8, table of contents.